Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. Other stock markets 24/07/2026			5-day change	1st Jan Change
961.21 ^PKR	-0.45%		-1.93%	-5.99%

19/05	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI
30/04	Highnoon Laboratories Limited Approves Final Cash Dividend for the Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	50,928	-	-
Change	-	11.36%	-5.99%	-	-
Enterprise Value (EV)	48,650	54,175	50,928	50,928	50,928
Change	-	11.36%	-5.99%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.68x	1.49x	1.33x
EV / Revenue	-	0x	1.68x	1.49x	1.33x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.68%	5.41%	6.24%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	961.21	961.21	961.21
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/3/25	7/4/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.68%	183M
ELI LILLY AND COMPANY	35.7x	12.68x	26.75x	0.57%	1,067B
JOHNSON & JOHNSON	28.24x	6.45x	17.87x	2.04%	635B
ABBVIE INC.	33.87x	7.65x	15.73x	2.65%	458B
ROCHE HOLDING AG	19.22x	4.69x	11.57x	2.82%	347B
NOVARTIS AG	21.56x	5.71x	14.24x	2.81%	295B
ASTRAZENECA PLC	21.1x	4.45x	12.31x	1.98%	262B
NOVO NORDISK A/S	14.14x	5.26x	10.84x	3.54%	216B
AMGEN INC.	24.66x	6.48x	11.43x	2.68%	203B
GILEAD SCIENCES, INC.	-46.58x	5.59x	30.88x	2.55%	161B
Average	16.88x	6.55x	16.85x	2.63%	364.32B
Weighted average by Cap.	24.88x	7.95x	18.70x	1.96%